X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs IPCA LABS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES IPCA LABS DIVIS LABORATORIES/
IPCA LABS
 
P/E (TTM) x 31.8 25.2 126.2% View Chart
P/BV x 7.0 3.7 188.7% View Chart
Dividend Yield % 0.6 0.1 506.7%  

Financials

 DIVIS LABORATORIES   IPCA LABS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
IPCA LABS
Mar-18
DIVIS LABORATORIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,142695 164.2%   
Low Rs533400 133.3%   
Sales per share (Unadj.) Rs146.6260.2 56.3%  
Earnings per share (Unadj.) Rs33.019.0 174.1%  
Cash flow per share (Unadj.) Rs38.433.1 116.2%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.20.2 654.0%  
Book value per share (Unadj.) Rs222.8213.0 104.6%  
Shares outstanding (eoy) m265.47126.20 210.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.72.1 271.4%   
Avg P/E ratio x25.328.9 87.8%  
P/CF ratio (eoy) x21.816.6 131.6%  
Price / Book Value ratio x3.82.6 146.2%  
Dividend payout %30.35.3 574.3%   
Avg Mkt Cap Rs m222,31869,120 321.6%   
No. of employees `00010.813.3 81.2%   
Total wages/salary Rs m4,5617,359 62.0%   
Avg. sales/employee Rs Th3,616.02,477.4 146.0%   
Avg. wages/employee Rs Th423.8555.2 76.3%   
Avg. net profit/employee Rs Th814.9180.6 451.1%   
INCOME DATA
Net Sales Rs m38,91532,836 118.5%  
Other income Rs m1,134418 271.4%   
Total revenues Rs m40,04933,254 120.4%   
Gross profit Rs m12,6174,505 280.1%  
Depreciation Rs m1,4251,777 80.2%   
Interest Rs m13240 5.5%   
Profit before tax Rs m12,3132,905 423.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543511 693.2%   
Profit after tax Rs m8,7702,394 366.3%  
Gross profit margin %32.413.7 236.3%  
Effective tax rate %28.817.6 163.6%   
Net profit margin %22.57.3 309.1%  
BALANCE SHEET DATA
Current assets Rs m45,35119,455 233.1%   
Current liabilities Rs m6,50710,076 64.6%   
Net working cap to sales %99.828.6 349.5%  
Current ratio x7.01.9 360.9%  
Inventory Days Days12798 129.4%  
Debtors Days Days9567 142.1%  
Net fixed assets Rs m21,16020,260 104.4%   
Share capital Rs m531252 210.3%   
"Free" reserves Rs m58,62526,633 220.1%   
Net worth Rs m59,15626,886 220.0%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m67,83241,173 164.7%  
Interest coverage x926.813.1 7,077.4%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.8 71.9%   
Return on assets %12.96.4 202.4%  
Return on equity %14.88.9 166.5%  
Return on capital %20.810.8 193.6%  
Exports to sales %047.6 0.0%   
Imports to sales %21.814.9 146.6%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs m8,4854,884 173.7%   
Fx inflow Rs m32,35915,642 206.9%   
Fx outflow Rs m9,0424,884 185.2%   
Net fx Rs m23,31710,759 216.7%   
CASH FLOW
From Operations Rs m7,7593,411 227.4%  
From Investments Rs m-4,783-1,354 353.2%  
From Financial Activity Rs m-3,142-1,304 240.9%  
Net Cashflow Rs m-166753 -22.0%  

Share Holding

Indian Promoters % 52.0 45.9 113.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 11.4 103.5%  
FIIs % 19.0 25.3 75.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 17.4 98.9%  
Shareholders   31,796 36,892 86.2%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 22, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - DISHMAN PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS